# OnCo record neosphere (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/neosphere/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "neosphere", "NCT00545688" ;
  schema:name "NeoSphere"@en ;
  schema:description "NeoSphere showed that blocking HER2 with two antibodies, pertuzumab and trastuzumab, alongside chemotherapy before surgery made HER2-positive breast tumours disappear completely more often than one antibody alone, which led to the first approval of a cancer drug for use before surgery."@en ;
  schema:url <https://onco.cc/trials/neosphere/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00545688> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/her2-positive-early-breast-cancer/>, <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:drugs <https://onco.cc/drugs/pertuzumab/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:people <https://onco.cc/people/luca-gianni/> .